About InNeuroCo
InNeuroCo is a Healthcare company based in Sunrise (United States) founded in 2014 by Marc Litzenberg and Daniel Sablyak, and was acquired by Integer in October 2023. Intermediate catheters and super distal access device for neurovascular surgery. InNeuroCo has raised $1.51 million across 3 funding rounds from investors including Integer. The company has 99 employees. Its chief executive, as recorded, is Marc Litzenberg. InNeuroCo offers products and services including Catheter Solutions and Medical Devices. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is INNEUROCO, INC. Its competitors include Q’Apel Medical, Zeta Surgical and Impulse Monitoring; 3 of its 3 listed competitors have raised funding.
Company details
InNeuroCo is a developer of devices for neurovascular surgeries. The companys Super Distal Access (SDA) is FDA 510(k) cleared (K161262) and it is indicated for the introduction of interventional devices into the peripheral and neuro vasculature. The companys Long Sheath also received FDA 510(k) clearance (K152876) and is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature. The company has partnered with Codman Neuro for the distribution of its intermediate catheter range.
- Headquarters Sunrise, United States
- Employees 99
- Founders Marc Litzenberg, Daniel Sablyak
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website inneuroco.com
- Social LinkedIn
- Acquired by Integer (Oct 2023)
- Legal Name Inneuroco, Inc
Products & Services of InNeuroCo
InNeuroCo offers a comprehensive portfolio of products and services, including Catheter Solutions and Medical Devices.
Develops innovative catheters for brain aneurysm treatments.
Creates life-saving tools for neurovascular procedures.
Funding Insights of InNeuroCo
InNeuroCo has successfully raised a total of $1.51M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $800.01 thousand completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.51M
- Total Rounds 3
- Last Round Debt – Conventional — $800,008
- First Round $925,000
(Jan 2015)
All 3 funding rounds of InNeuroCo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $800,008 | Debt – Conventional | – | – | – |
| Jun 2015 | $580,044 | Seed | – | – | – |
| Jan 2015 | $925,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in InNeuroCo
InNeuroCo has secured backing from 1 investor. Prominent investors backing the company include Integer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical device components are developed and manufactured for healthcare markets. | 1970 | integer.net | Frisco, United States |
Investor details for InNeuroCo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InNeuroCo
9 people are tracked at InNeuroCo (2 in leadership, 7 in team); the tracked headcount is 99.
| Name | Role | Group |
|---|---|---|
Marc Litzenberg | Founder & CEO | Leadership |
Daniel Sablyak | Co-Founder & CTO | Leadership |
Candace Greenland | New Product Development Engineer | Team |
Sana Wahid | Sr. New Product Development Engineer | Team |
Nerea Olazar | QC Manager | Team |
Nicolas Perez de Guzman | Research And Development Engineer | Team |
Rayniel Perez | Manufacturing Operations Manager | Team |
Juan-Carlos Diaz | Principal Manufacturing Engineer | Team |
Carmen Mercado | Document Control Specialist | Team |
Complete people profiles for InNeuroCo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InNeuroCo
4 dated milestones of InNeuroCo across 9 years, from founding to its latest funding, stage changes and deals.
- Founded InNeuroCo is founded.
- Funding First funding round of $925K.
- Funding Latest funding round, Debt – Conventional, of $800K.
- Exit Acquired by Integer.
Competitors of InNeuroCo
InNeuroCo has 3 listed competitors in our database, 3 of them funded. They include Q’Apel Medical, Zeta Surgical and Impulse Monitoring.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qapelmedical.com | 2019 | Fremont, United States | $51.9M | 100 | Medical devices for neurovascular disorder treatments are provided. | |
| zetasurgical.com | 2016 | Boston, United States | $8.16M | 7 | AI-based navigation and robotics systems for surgeries are developed. | |
| impulsemonitoring.com | 2002 | Columbia, United States | $13.5M | Intraoperative neurophysiological monitoring is conducted for spinal and brain surgeries. |
Detailed competitors of InNeuroCo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as InNeuroCo (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inneuroco
Complete news archive for InNeuroCo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InNeuroCo
InNeuroCo was founded in 2014 and raised its 1st funding round 1 year after it was founded.
InNeuroCo is headquartered in Sunrise, United States. It is registered at Sunrise, Florida, United States.
Marc Litzenberg is the CEO of InNeuroCo, as recorded in our data. They have also founded this company.
InNeuroCo is a funded company, having raised a total of $1.51M across 3 funding rounds to date. The company's 1st funding round was a Seed of $925K, raised on Jan 2015.
InNeuroCo has 99 employees.
InNeuroCo is a developer of devices for neurovascular surgeries. The companys Super Distal Access (SDA) is FDA 510(k) cleared (K161262) and it is indicated for the introduction of interventional devices into the peripheral and neuro vasculature. The companys Long Sheath also received FDA 510(k) clearance (K152876) and is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature. The company has partnered with Codman Neuro for the distribution of its intermediate catheter range.
InNeuroCo's top competitors include Zeta Surgical, Q’Apel Medical and Impulse Monitoring.
InNeuroCo offers Catheter Solutions and Medical Devices.
InNeuroCo has 1 investor. Key investors include Integer.
InNeuroCo operates through Inneuroco, Inc.
Yes. InNeuroCo was acquired by Integer in October 2023.

